Work

Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer

Year: 2019

Type: conference-abstract

Source: Clinical Trials

DOI: 10.1158/1538-7445.sabcs18-ct015

Authors: Andreas Schneeweiss, Dagmer Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Cynthia Ma, Ian Krop, Sara Hurvitz, Christine Rentzsch, Marion Rudolph, Oliver Boix, Gary Wilkinson, Lars Lindbom, Eleni Lagkadinou, Matthias Ocker

Institutions: German Cancer Research Center, National Center for Tumor Diseases, Kantonsspital St. Gallen, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Washington University in St. Louis, Dana-Farber Cancer Institute, University of California, Los Angeles, Bayer (Germany)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4242747675

Cites:

Cited by:

Related to: 10